Table 1.
Scorea | Biological target | Action | Drugs | p value |
---|---|---|---|---|
+ | Topoisomerase II | Inhibitor | Amsacrine, amonafide, teniposide, etoposide, idarubicin | 2.829 × 10–4 |
+ | HDAC | Inhibitor | Panobinostat, scriptaid, dacinostat, vorinostat, trichostatin A | 1.451 × 10–4 |
+ | Protein kinase C delta | Activator | Phorbol-12-myristate-13-acetate, ingenol | 3.172 × 10–3 |
+ | Histone lysine methyltransferase | Inhibitor | Chaetocin | |
+ | ARFGAP1 | Inhibitor | QS11 | |
+ | PDK1 | Inhibitor | BX795 | |
+ | Retinoic acid receptor beta | Inhibitor | Le135 | |
+ | Arginase | Inhibitor | Inhibitor Bec | |
+ | JAK2/STAT3 | Inhibitor | Cucurbitacin I | |
+ | Fatty acid synthetase | Inhibitor | Cerulenin | |
+ | Src, Bcr-Abl tyrosine kinase | Inhibitor | AG957 | |
+ | PLD2 | Inhibitor | CAY10594 | |
+ | IKKβ | Inhibitor | Parthenolide | |
+ | IMPDH1 | Inhibitor | Mycophenolic acid | |
+ | FTL3 | Inhibitor | Midostaurin | |
+ | DNA | Crosslinker | Mitomycin C | |
+ | Tubulin | Inhibitor | Vinblastine | |
+ | Hsp90 | Inhibitor | Radicol | |
+ | Multiple targets | Inhibitor | Resveratrol | |
– | PI3K | Inhibitor | PI828, GDC0941, NVP-BEZ235,PP110, TGX115 | 4.915 × 10–6 |
– | mTOR | Inhibitor | NVP-BEZ235, AZD8055, TGX115, Ku0063794 | 1.792 × 10–5 |
– | CDK | Inhibitor | BML259, indirubin | 1.463 × 10–2 |
– | IKBalfa | Inhibitor | Evodiamine | |
– | Farnesyltransferase | Inhibitor | Tipifarnib | |
– | IGF1R | Inhibitor | Linsitinib | |
– | MAP2K1 | Inhibitor | Selumetinib | |
– | CHK1 | Inhibitor | SB218078 | |
– | Piruvate kinase | Inhibitor | M2PK activator | |
– | Rho kinase | Inhibitor | Rho kinase inhibitor III | |
– | Voltage-dependent calcium channel | Inhibitor | Nifedipine | |
– | Braf | Inhibitor | Vemurafenib |
Table presents significant drugs with their biological target and their mechanism of action. p value calculated for groups of drugs with the same target using Fisher’s exact test
CDK cyclin-dependent kinase, HDAC histone deacetylase, mTOR mammalian target of rapamycin, PI3K phosphoinositol 3 kinase
a + drugs with positive similarity score, – drugs with negative similarity score in regard to SLE signatures